American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).
about
Approach to the Triple Negative Breast Cancer in New Drugs AreaImaging Diagnostic and Therapeutic Targets: Steroid Receptors in Breast CancerProgesterone and Overlooked Endocrine Pathways in Breast Cancer PathogenesisBiomarker validation and testingEstrogen Receptor Status and the Future Burden of Invasive and In Situ Breast Cancers in the United States.Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State.One-step preservation of phosphoproteins and tissue morphology at room temperature for diagnostic and research specimensHigh expression of class III β-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancerDecoding the usefulness of non-coding RNAs as breast cancer markersThe role of estrogen, progesterone and aromatase in human non-small-cell lung cancerNew breast cancer prognostic factors identified by computer-aided image analysis of HE stained histopathology imagesDevelopment of multigene expression signature maps at the protein level from digitized immunohistochemistry slidesImpact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivationTherapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer.Involvement of macrophage migration inhibitory factor and its receptor (CD74) in human breast cancer.US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapyVascular measurements correlate with estrogen receptor statusRisk of second breast cancers after lobular carcinoma in situ according to hormone receptor statusA tissue quality index: an intrinsic control for measurement of effects of preanalytical variables on FFPE tissue.Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study.Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profilingA nomogram to predict the probability of axillary lymph node metastasis in female patients with breast cancer in China: A nationwide, multicenter, 10-year epidemiological study.Development of a Breast Cancer Treatment Program in Port-au-Prince, Haiti: Experiences From the Field.Cytochrome c1 in ductal carcinoma in situ of breast associated with proliferation and comedo necrosis.A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in situ of the breast.Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified?Long-term survival analysis of korean breast cancer patients at a single center: improving outcome over time.miR-221/222 control luminal breast cancer tumor progression by regulating different targets.Pathogenesis, prevention, diagnosis and treatment of breast cancer.Estrogen receptor, progesterone receptor, interleukin-6 and interleukin-8 are variable in breast cancer and benign stem/progenitor cell populations.Use of imputed population-based cancer registry data as a method of accounting for missing information: application to estrogen receptor status for breast cancer.Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences.Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 statusInvasive breast carcinoma cells from patients exhibit MenaINV- and macrophage-dependent transendothelial migration.The difference in prognostic factors between early recurrence and late recurrence in estrogen receptor-positive breast cancer: nodal stage differently impacts early and late recurrence.Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology.Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG)Methylation of tumor suppressor genes is related with copy number aberrations in breast cancerExpression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
P2860
Q26744054-984BD78C-A1C2-4BAE-A824-381225DDF476Q26772868-92E38CD6-327F-4EFA-A9E0-ADDB7A736765Q26799158-3EA42054-8A87-4773-B977-091861AC737DQ26863672-D8A736AA-794E-4FCF-818B-2123B7907BF4Q27300398-AC5F340F-E61B-481E-ADF6-FDD53BEEC39AQ27300459-47C0E926-2C79-4E38-8E96-E3964D397D70Q27323289-9C4E85FF-9FDC-4FBD-98D1-57FAD737FDC0Q27851983-EBB146D2-73F9-45F5-B9B9-CC1EEE1F6F1FQ28069370-6D9952A9-014F-4F48-93E2-AF4ED17F17A0Q28397662-21AA950E-0934-4246-A5DE-D169ACE77730Q28646873-BBE6DD19-3BC6-4F96-8394-3B2946A76D24Q28731283-0B1DCF6E-C864-412A-97E8-D8EB01618BDEQ30369607-EE9D8B98-55AF-45BB-8998-95B348082F85Q30419997-B61985D7-B491-4AB1-AB78-A35A745E2D61Q30435034-151E1CD4-1322-41FA-9D92-4DBBAE562164Q30665329-A68AFCCE-CC4C-4E76-8F17-AC08394F6CD5Q33573055-6D518C47-362F-48C1-BDE8-E88FDB12F022Q33577008-2F30E799-EEF8-42F2-A21E-1E529631AE94Q33632366-A9066643-4E3F-4601-B2B4-2C1574B46A80Q33649620-14A4C3CC-45AF-4DC4-AE84-47C021BE47D0Q33688726-70731A34-36EC-4028-A653-903B85647ED7Q33716499-1ABB99AA-26A8-4F9F-BEAD-17DF6E349ED4Q33798836-B58BC051-AD1A-48A1-B5A5-4FC11325F185Q33873186-627CB1A8-5F46-48CC-BBA6-E161875D3A6FQ33873665-052332E3-DBF0-409D-8132-A2589A3282C5Q33914381-77D41BC3-1580-4AFB-B546-302363E9DC20Q33932665-22235B41-0FB8-475A-AB22-0480E4174109Q33941558-C42E5F80-0372-4578-B6C2-F2BCE6FAA571Q33952998-2D50B16B-8029-4954-8F87-3AF19E973672Q34023647-AEFC6DB1-7201-4534-A15B-03D98413823EQ34309582-7A5B1A0B-4B9D-4BE6-819B-43FBC100F07BQ34355792-8A272691-6D42-4FA6-959C-0087EC220383Q34654793-444AD302-4E27-4098-AFAE-70F5956BA46BQ34705321-68E95095-D26C-49BB-94A1-C3F63AD7E1E1Q34706851-29189565-1C72-4746-93FB-40E4CDEBC69FQ34744234-B07E9CAA-5C77-4973-8CB8-1DB596CE5860Q34897615-FC82027C-EC19-460F-BF8E-EAD10E2D47BCQ34907190-373B35B1-CDF9-4970-A88D-4814AF857CD4Q34991280-7AA76E07-425B-4D15-861B-62EB9D0A9E3BQ35040111-53C1FBBD-FBFD-44A4-96B4-2C63E312178E
P2860
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
American Society of Clinical O ...... t cancer (unabridged version).
@en
American Society of Clinical O ...... one receptors in breast cancer
@nl
type
label
American Society of Clinical O ...... t cancer (unabridged version).
@en
American Society of Clinical O ...... one receptors in breast cancer
@nl
prefLabel
American Society of Clinical O ...... t cancer (unabridged version).
@en
American Society of Clinical O ...... one receptors in breast cancer
@nl
P2093
P50
P1476
American Society of Clinical O ...... t cancer (unabridged version).
@en
P2093
Anthony Rhodes
Antonio C Wolff
C Kent Osborne
D Craig Allred
Daniel F Hayes
Daniel Visscher
David G Hicks
Emina Emilia Torlakovic
Fred C G Sweep
Glenn Francis
P304
P356
10.1043/1543-2165-134.7.E48
P577
2010-07-01T00:00:00Z